Brief: Cardiff Oncology Announces New Patent With Claims For Use Of Onvansertib In Treating KRAS Mutated mCRC
19/11/2024 13:18
Nov 19 (Reuters) - Cardiff Oncology Inc CRDF.O :
* CARDIFF ONCOLOGY INC: ANNOUNCES NEW PATENT WITH CLAIMS FOR
USE
OF ONVANSERTIB IN TREATING KRAS MUTATED MCRC
* CARDIFF ONCOLOGY INC: PROTECTS USE OF ONVANSERTIB IN
COMBINATION
WITH STANDARD OF CARE IN KRAS MUTATED MCRC SETTING THROUGH 2043
Source text: ID:nGNXbc8qGr
Further company coverage: CRDF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering